CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corvus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.65+0.13 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $891.35M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.61 (+37.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $891.35M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.96
- Dividend yield
- –
- Free cash flow yield
- -5.07%
Fundamentals
- Net income
- -$54.13M
- EPS, diluted
- -$0.61
- Free cash flow
- -$45.23M
- Book value per share
- $2.44
- Diluted shares
- 92M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Operating income
-$56.96M
Net income
-$54.13M
EPS, diluted
-$0.61
Free cash flow
-$45.23M
Reported periodTrailing twelve months